Last reviewed · How we verify
ex vivo Activated Immune Cells
ex vivo Activated Immune Cells is a Small molecule drug developed by B & Y Technologies. It is currently in Phase 1 development.
At a glance
| Generic name | ex vivo Activated Immune Cells |
|---|---|
| Sponsor | B & Y Technologies |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients
- Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC (PHASE2)
- Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (PHASE2, PHASE3)
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (PHASE2)
- Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
- A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors (EARLY_PHASE1)
- A Clinical Study on TILs for the Treatment of Advanced Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ex vivo Activated Immune Cells CI brief — competitive landscape report
- ex vivo Activated Immune Cells updates RSS · CI watch RSS
- B & Y Technologies portfolio CI
Frequently asked questions about ex vivo Activated Immune Cells
What is ex vivo Activated Immune Cells?
ex vivo Activated Immune Cells is a Small molecule drug developed by B & Y Technologies.
Who makes ex vivo Activated Immune Cells?
ex vivo Activated Immune Cells is developed by B & Y Technologies (see full B & Y Technologies pipeline at /company/b-y-technologies).
What development phase is ex vivo Activated Immune Cells in?
ex vivo Activated Immune Cells is in Phase 1.
Related
- Manufacturer: B & Y Technologies — full pipeline